生物感測器市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

全球生物感測器市場估值於2023 年達到301 億美元，預計2024 年至2032 年複合年成長率為7.7%。解決方案的需求不斷增加。市場分為穿戴式式和非穿戴式生物感測器。由於整合到用於即時 (POC) 測試的診斷設備中，非穿戴式生物感測器在 2023 年佔據了 64.2% 的巨大佔有率。這些生物感測器具有多種優點，包括易於使用、高精度以及無需用戶持續輸入即可快速提供診斷結果的能力。

在 POC 設定中，非穿戴式生物感測器對於快速測試和診斷非常有價值，可以加快治療決策並改善患者治療效果。感測器技術的進步，例如增強的靈敏度、小型化以及與數位平台的兼容性，進一步增強了它們的功能和吸引力。從技術上講，生物感測器市場分為電化學、光學、熱學、壓電和其他類別。電化學生物感測器因其高靈敏度、特異性和快速反應時間而在 2023 年以 125 億美元的收入引領市場，使其成為醫療應用的理想選擇。

這些生物感測器是血糖儀等設備的核心，糖尿病患者廣泛使用這些設備來監測血糖水平。生物感測器市場也按最終用途細分，涵蓋現場檢測、家庭醫療診斷、研究實驗室和其他領域。到 2032 年，即時檢測 (POC) 領域預計將達到 298 億美元。這種迅速反應對於管理緊急情況和緊急情況、減少等待時間以及促進即時臨床干預至關重要。

這種效率對於緊急護理和慢性病管理尤其有益。從地區來看，美國在北美生物感測器市場佔據主導地位，到 2023 年將產生 95 億美元的收入，預計在預測期內將大幅成長。美國的高額醫療支出和有利的保險政策鼓勵對先進生物感測器技術的投資，提高患者的可及性和負擔能力。總而言之，在醫療診斷和照護端應用對高效醫療保健解決方案的需求的推動下，生物感測器市場正處於強勁的成長軌道。的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 生物感測器在醫學領域的應用日益廣泛
    • 全球糖尿病盛行率上升
    • 亞太地區和歐洲對攜帶式生物感測器的高需求
    • 技術進步
  • 產業陷阱與挑戰
    • 嚴格的監管場景
    • 產品開發成本高
• 成長潛力分析
• 監管環境
  • 美國
  • 歐洲
• 技術景觀
  • 當前產業趨勢
  • 啟動場景
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 穿戴式生物感測器
• 非穿戴式生物感測器

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

• 主要趨勢
• 電化學
• 光學的
• 熱的
• 壓電式
• 其他技術

第 7 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 血糖檢測
• 膽固醇測試
• 血氣分析
• 妊娠檢測
• 藥物發現
• 傳染病檢測
• 其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 照護端測試
• 家庭醫療保健診斷
• 研究實驗室
• 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 瑞士
• 亞太地區
  • 中國
  • 日本
  • 印度
• 拉丁美洲
  • 巴西
  • 墨西哥
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯

第 10 章：公司簡介

• Abbott Laboratories
• Ascensia Diabetes Care Holdings
• Bio-Rad Laboratories
• Biosensors International Group
• Danaher Corporation
• Dexcom
• F. Hoffmann-La Roche
• LifeScan
• Masimo
• Nova Biomedical
• Pinnacle Technology
• QTL Biosystems
• Siemens Healthineers
• TE Connectivity Corporation
• Thermo Fisher Scientific

The Global Biosensors Market reached a valuation of USD 30.1 billion in 2023 and is anticipated to grow at a 7.7% CAGR from 2024 to 2032. The primary driver behind this growth is the rising global prevalence of diabetes and increasing demand for efficient monitoring and diagnostic solutions. The market is divided into wearable and non-wearable biosensors. Non-wearable biosensors held a substantial 64.2% share in 2023, thanks to their integration into diagnostic devices used for point-of-care (POC) testing. These biosensors provide several benefits, including ease of use, high accuracy, and the ability to deliver quick diagnostic results without continuous user input.

In POC settings, non-wearable biosensors are invaluable for rapid testing and diagnosis, leading to faster treatment decisions and improved patient outcomes. Advances in sensor technology, such as enhanced sensitivity, miniaturization, and compatibility with digital platforms, further boost their functionality and appeal. Technologically, the biosensors market is segmented into electrochemical, optical, thermal, piezoelectric, and other categories. Electrochemical biosensors led the market with USD 12.5 billion in revenue in 2023, driven by their high sensitivity, specificity, and quick response times, making them ideal for medical applications.

These biosensors are central to devices like glucose meters, widely used by diabetic patients to monitor blood sugar levels. The biosensors market is also segmented by end-use, covering point-of-care testing, home healthcare diagnostics, research labs, and other sectors. The point-of-care testing (POC) segment is expected to reach USD 29.8 billion by 2032. Biosensors are key to POC testing, offering rapid results that enable quick diagnosis and decision-making. This prompt response is crucial in managing acute conditions and emergencies, reducing waiting times, and facilitating immediate clinical interventions.

Such efficiency is especially beneficial in emergency care and chronic disease management. Regionally, the U.S. dominated the North American biosensors market, generating USD 9.5 billion in revenue in 2023, with substantial growth expected over the forecast period. High healthcare expenditure and favorable insurance policies in the U.S. encourage investment in advanced biosensor technologies, enhancing accessibility and affordability for patients. In summary, the biosensors market is on a strong growth trajectory, driven by the demand for efficient healthcare solutions across medical diagnostics and point-of-care applications.Innovations in technology and favorable conditions in key regions like the U.S. are expected to further propel market growth through 2032.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing application of biosensors in medical field
    • 3.2.1.2 Rising prevalence of diabetes globally
    • 3.2.1.3 High demand for portable biosensors in Asia Pacific and Europe
    • 3.2.1.4 Technological advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory scenario
    • 3.2.2.2 High cost of product development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technological landscape
  • 3.5.1 Current trends in the industry
  • 3.5.2 Start-up scenario
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Wearable biosensors
• 5.3 Non-wearable biosensors

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Electrochemical
• 6.3 Optical
• 6.4 Thermal
• 6.5 Piezoelectric
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Blood glucose testing
• 7.3 Cholesterol testing
• 7.4 Blood gas analysis
• 7.5 Pregnancy testing
• 7.6 Drug discovery
• 7.7 Infectious disease testing
• 7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Point of care testing
• 8.3 Home healthcare diagnostics
• 8.4 Research laboratories
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Russia
  • 9.3.7 Switzerland
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Ascensia Diabetes Care Holdings
• 10.3 Bio-Rad Laboratories
• 10.4 Biosensors International Group
• 10.5 Danaher Corporation
• 10.6 Dexcom
• 10.7 F. Hoffmann-La Roche
• 10.8 LifeScan
• 10.9 Masimo
• 10.10 Nova Biomedical
• 10.11 Pinnacle Technology
• 10.12 QTL Biosystems
• 10.13 Siemens Healthineers
• 10.14 TE Connectivity Corporation
• 10.15 Thermo Fisher Scientific